Concurrent Investment Advisors LLC Purchases 2,256 Shares of STERIS plc $STE

Concurrent Investment Advisors LLC boosted its position in shares of STERIS plc (NYSE:STE) by 24.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,563 shares of the medical equipment provider’s stock after acquiring an additional 2,256 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in STERIS were worth $2,931,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in STE. Jones Financial Companies Lllp raised its stake in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 349 shares during the period. Goldman Sachs Group Inc. increased its position in STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares during the period. Empowered Funds LLC increased its position in shares of STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 319 shares during the period. Woodline Partners LP increased its position in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after purchasing an additional 2,372 shares during the period. Finally, Jane Street Group LLC increased its position in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after purchasing an additional 5,803 shares during the period. Institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings lowered STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Trading Up 0.2%

Shares of STE stock opened at $222.35 on Tuesday. The company has a market cap of $21.81 billion, a P/E ratio of 31.01 and a beta of 1.07. The stock has a 50 day simple moving average of $228.31 and a two-hundred day simple moving average of $245.22. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a fifty-two week low of $209.98 and a fifty-two week high of $269.44.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Research analysts forecast that STERIS plc will post 10.22 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th were issued a dividend of $0.63 per share. The ex-dividend date was Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. STERIS’s payout ratio is currently 35.15%.

Insider Activity at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director owned 705 shares in the company, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.07% of the stock is currently owned by corporate insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.